$CVM

CEL SCI CORP

CIK:0000725363|SEC Filings

CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Operating expenses:
Research and development	$ 3,649,940	$ 3,739,948	$ 11,094,085	$ 12,184,276
General & administrative	1,907,345	1,748,935	5,158,015	6,592,128
Total operating expenses	5,557,285	5,488,883	16,252,100	18,776,404
Operating loss	(5,557,285)	(5,488,883)	(16,252,100)	(18,776,404)
Interest expense, net	(110,240)	(172,050)	(315,514)	(520,439)
Other expense	0	(3,771)	(35,108)	(13,312)
Net loss	(5,667,525)	(5,664,704)	(16,602,722)	(19,310,155)
Net loss available to common shareholders	$ (5,667,525)	$ (5,664,704)	$ (16,602,722)	$ (19,310,155)
Net loss per common share - basic and diluted	$ (0.47)	$ (1.36)	$ (1.76)	$ (6.34)
Weighted average common shares outstanding - basic and diluted	12,116,390	4,150,702	9,423,006	3,046,400

CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)	9 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (16,602,722)	$ (19,310,155)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	2,867,193	2,924,303
Non-cash lease expense, net of lease payments	33,605	(2,970)
Share-based payments for services	271,159	587,285
Equity based compensation	1,348,750	1,470,491
Common stock contributed to 401(k) plan	179,606	164,510
Shares issued for settlement of clinical development costs	479,790	350,885
Loss on patent impairment	35,108	13,312
(Increase)/decrease in assets:
Prepaid expenses	(370,182)	(13,874)
Supplies used for R&D and manufacturing	9,894	622,831
Deposits	(720)	(4,000)
Increase/(decrease) in liabilities:
Accounts payable	(41,318)	2,444
Accrued expenses	(259,699)	(60,490)
Due to employees	(26,184)	806,214
Net cash used in operating activities	(12,075,720)	(12,449,214)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment	0	(32,954)
Net cash used in investing activities	0	(32,954)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock and pre-funded warrants	9,700,000	12,560,300
Payments of stock issuance costs	(1,093,620)	(1,531,832)
Proceeds from the purchase of stock by officers and directors	729,000	0
Proceeds from notes payable	0	350,000
Payments of notes payable	0	(350,000)
Payments on obligations under finance leases	(1,685,739)	(1,491,617)
Net cash (used in) provided by financing activities	7,649,641	9,536,851
NET DECREASE IN CASH AND CASH EQUIVALENTS	(4,426,079)	(2,945,317)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	10,953,460	4,738,173
CASH AND CASH EQUIVALENTS, END OF PERIOD	6,527,381	1,792,856
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Finance lease obligation included in accounts payable	1,505	838
Changes to operating right of use assets and liabilities	312,725	0
Obligations paid with issuance of common stock	270,694	583,447
Financing costs included in current liabilities	165,530	168,740
SUPPLEMENTAL DISCLOSURE OF CASH FLOWS:
Cash paid for interest	$ 458,046	$ 592,644

CONDENSED BALANCE SHEETS - USD ($)	Jun. 30, 2026	Sep. 30, 2025
Current assets:
Cash and cash equivalents	$ 6,527,381	$ 10,953,460
Prepaid expenses	702,018	332,301
Supplies used for R&D and manufacturing	266,763	303,282
Deposits	7,805	7,085
Total current assets	7,503,967	11,596,128
Finance lease right-of-use assets	4,196,553	5,548,186
Operating lease right-of-use assets	1,442,285	1,274,780
Property and equipment, net	4,578,795	6,079,295
Patent costs, net	69,688	119,856
Deposits	2,319,101	2,319,101
Supplies used for R&D and manufacturing	1,245,027	1,218,402
Total assets	21,355,416	28,155,748
Current Liabilities:
Accounts payable	1,023,200	1,061,351
Accrued expenses	462,121	711,820
Due to employees	890,404	916,588
Finance lease obligation, current portion	2,487,377	2,273,797
Operating lease obligation, current portion	216,569	166,990
Total current liabilities	5,079,671	5,130,546
Finance lease liabilities, net of current portion	3,784,436	5,684,127
Operating lease liabilities, net of current portion	1,410,521	1,258,990
Other liabilities	125,000	125,000
Total liabilities	10,399,628	12,198,663
STOCKHOLDERS' EQUITY
Preferred stock, $0.01 par value; 200,000 shares authorized; 0 shares issued and outstanding	0	0
Common stock, $0.01 par value; 600,000,000 shares authorized; 17,588,653 and 8,015,701 shares issued and outstanding at June 30, 2026 and September 30, 2025, respectively	173,077	80,157
Additional paid-in capital	566,808,349	555,299,844
Accumulated deficit	(556,025,638)	(539,422,916)
Total stockholders' equity	10,955,788	15,957,085
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 21,355,416	$ 28,155,748